Assessing Sedentary Behaviour in Adults With Type 2 Diabetes - A Randomized Controlled Trial

NCT ID: NCT05505864

Last Updated: 2023-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this health behaviour change research study is to assist adults with T2D in achieving the Canadian 24-hour sedentary behaviour movement guidelines.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adults with type 2 diabetes (T2D) are less active and accumulate more sedentary behaviour (SB) than those without. Among adults with T2D, increased SB is associated with increased mortality after adjusting for physical activity. Canadian 24-hour SB movement guidelines recommend limiting SB to ≤8 hours, no more than 3 hours of recreational screen time, and breaking up long periods of SB as often as possible. Therefore, the purpose of this research study is for adults with T2D to achieve these SB Canadian 24-hour SB movement guidelines. To address this purpose, we will be conducting a six-week two-arm repeated measures randomized control trial. The intervention group will receive a theory-based behaviour change counselling session through zoom at week 0, mobile phone application at weeks 2 and 4 that encourage participants to create their own personal and specific action plans and coping strategies, and daily text messages that motivate participants to reduce and break up their SB. The control group will receive no intervention. The primary objective of the study is to reduce SB, while the secondary objectives are to break up SB, reduce screen time, improve quality of life, determine the perceptions towards the intervention, and validate the SB questionnaires. SB will be collected in the form of total daily SB, frequency of SB breaks, and duration of SB breaks. These variables will be measured through a SB and quality of life questionnaires that will be delivered through a downloadable mobile phone application. Outcome measures will be compared within and between groups to detect differences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sedentary Behavior Diabetes Mellitus, Type 2 Adult ALL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

* Participants in the intervention group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.
* Participants in the intervention group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 app at week 0, 2, 4, 6, and 12.
* Participants in the intervention group will receive a one-on-one behavioural counselling session online through zoom at week 0 to create personalized action plans and coping strategies to reduce and break up sedentary behaviour. The participant will update these action plans and coping strategies at the end of week 2 and 4 on the SEMA3 app.
* Participants in the intervention group will receive tailored text messages the day after receiving their one-on-one counselling session for a 6-week period.
* Participants in the intervention will receive one-on-one qualitative interview on zoom at week 6 to explore participants overall experience engaging in the intervention.

Group Type EXPERIMENTAL

Health Action Process Approach (HAPA)

Intervention Type BEHAVIORAL

Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change

Control Group

* Participants in the control group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.
* Participants in the control group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 mobile app at week 0, 2, 4, 6, and 12.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Health Action Process Approach (HAPA)

Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* diagnosed with type 2 diabetes
* access to a smart phone with internet connection
* be able to read, write, and speak in english

Exclusion Criteria

* any medical or physical limitation that would prevent standing, stretching, and/or light physical activity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Western University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Siobhan Smith

Dr Harry Prapavessis, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Harry Prapavessis, PhD

Role: PRINCIPAL_INVESTIGATOR

Western University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harry Prapavessis

London, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Harry Prapavessis, PhD

Role: CONTACT

519 661-2111 ext. 80173

Siobhan Smith, MA

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Harry Prapavessis, PhD

Role: primary

519 661-2111 ext. 80173

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

120585

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Alberta Diet: Effectiveness Study
NCT01625507 COMPLETED PHASE2
Prevention and Choice for Type 2
NCT06377020 COMPLETED NA